Hims & Hers Reports Q1 Net Loss, Lower EBITDA Amid Restructuring & Legal Accruals

summarizeSummary

Hims & Hers Health, Inc. reported a significant net loss of $92.1 million and a substantial decrease in Adjusted EBITDA for Q1 2026, driven by restructuring charges related to its weight loss offerings and a $15 million legal accrual for an FTC investigation.

check_boxKey Events

• Significant Q1 Net Loss

  The company reported a net loss of $92.1 million for Q1 2026, a sharp decline from a $49.5 million net income in Q1 2025.

• Adjusted EBITDA Decline

  Adjusted EBITDA decreased significantly to $44.3 million in Q1 2026 from $91.1 million in Q1 2025.

• Restructuring Charges Incurred

  $33.5 million in non-recurring charges were incurred due to a strategic shift in the U.S. weight loss offering, impacting cost of revenue and operations.

• FTC Investigation Accrual

  An accrual of $15.0 million was recorded for estimated probable losses related to an FTC investigation into privacy, advertising, and cancellation practices, with potential for higher liability.

auto_awesomeAnalysis

This quarterly report reveals a significant deterioration in Hims & Hers' financial performance, with a substantial net loss and reduced Adjusted EBITDA, contrasting sharply with prior profitability. The results are heavily impacted by a $33.5 million restructuring charge for its U.S. weight loss offerings and a $15 million accrual for an ongoing FTC investigation, which carries a risk of higher future liability. Furthermore, the disclosure of an SEC investigation into compounded semaglutide adds a serious regulatory overhang. While the company is pursuing large acquisitions like Eucalyptus to drive future growth, the immediate financial challenges and increasing legal/regulatory scrutiny present considerable headwinds. The decline in gross margin also points to operational pressures. This filing confirms and elaborates on the negative aspects of the Q1 results, providing critical details for investors.